Abstract:Background The pentose phosphate pathway (PPP) plays a crucial role in the material and energy metabolism in cancer cells. Targeting 6-phosphogluconate dehydrogenase (6PGD), the rate-limiting enzyme in the PPP metabolic process, to inhibit cellular metabolism is an effective anticancer strategy. In our previous study, we have preliminarily demonstrated that gambogic acid (GA) induced cancer cell death by inhibiting 6PGD and suppressing PPP at the cellular level. However, it is unclear whether GA could suppress cancer cell growth by inhibiting PPP pathway in mouse model. Purpose This study aimed to confirm that GA as a covalent inhibitor of 6PGD protein and to validate that GA suppresses cancer cell growth by inhibiting the PPP pathway in a mouse model. Methods Cell viability was detected by CCK-8 assays as well as flow cytometry. The protein targets of GA were identified using a chemical probe and activity-based protein profiling (ABPP) technology. The target validation was performed by in-gel fluorescence assay, the Cellular Thermal Shift Assay (CETSA). A lung cancer mouse model was constructed to test the anticancer activity of GA. RNA sequencing was performed to analyze the global effect of GA on gene expression. Results The chemical probe of GA exhibited high biological activity in vitro . 6PGD was identified as one of the binding proteins of GA by ABPP. Our findings revealed a direct interaction between GA and 6PGD. We also found that the anti-cancer activity of GA depended on reactive oxygen species (ROS), as evidenced by experiments on cells with 6PGD knocked down. More importantly, GA could effectively reduce the production of the two major metabolites of the PPP in lung tissue and inhibit cancer cell growth in the mouse model. Finally, RNA sequencing data suggested that GA treatment significantly regulated apoptosis and hypoxia-related physiological processes. Conclusion These results demonstrated that GA was a covalent inhibitor of 6PGD protein. GA effectively suppressed cancer cell growth by inhibiting the PPP pathway without causing significant side effects in the mouse model. Our study provides in vivo evidence that elucidates the anticancer mechanism of GA, which involves the inhibition of 6PGD and modulation of cellular metabolic processes.

Gambogic acid suppresses the pentose phosphate pathway by covalently inhibiting 6PGD protein in cancer cells

Gambogic acid exhibits promising anticancer activity by inhibiting the pentose phosphate pathway in lung cancer mouse model

Gambogic Acid Inhibits Tumor Cell Adhesion by Suppressing Integrin Β1 and Membrane Lipid Rafts-Associated Integrin Signaling Pathway.

O-GlcNAcylation of G6PD Promotes the Pentose Phosphate Pathway and Tumor Growth

Gambogic Acid Inhibits LPS-induced Macrophage Pro-Inflammatory Cytokine Production Mainly Through Suppression of the P38 Pathway

Gambogic Acid Inhibits Gastric Cancer Cell Proliferation through Necroptosis

Gambogic acid impairs tumor angiogenesis by targeting YAP/STAT3 signaling axis.

Unveiling Gambogenic Acid as a Promising Antitumor Compound: A Review

Gambogic Acid Mediates Apoptosis As a P53 Inducer Through Down-Regulation of Mdm2 in Wild-Type P53-Expressing Cancer Cells

6-Phosphogluconate dehydrogenase promotes glycolysis and fatty acid synthesis by inhibiting the AMPK pathway in lung adenocarcinoma cells

Gambogenic acid induction of apoptosis in a breast cancer cell line.

Enhancement of anticancer efficacy of chemotherapeutics by gambogic acid against gastric cancer cells.

Gambogic Acid Inhibits Invasion Of Osteosarcoma Via Upregulation Of Timp-1

6-Phosphogluconate Dehydrogenase Links Oxidative PPP, Lipogenesis and Tumour Growth by Inhibiting LKB1–AMPK Signalling

Synergistic Anti-Proliferative Effects of Gambogic Acid with Docetaxel in Gastrointestinal Cancer Cell Lines

Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells.

Gambogic acid suppresses nasopharyngeal carcinoma via rewiring molecular network of cancer malignancy and immunosurveillance

Synthesis and Biological Evaluation of Anthraquinone Derivatives As Allosteric Phosphoglycerate Mutase 1 Inhibitors for Cancer Treatment.

Effects of Carnosic and Usnic Acid on Pentose Phosphate Pathway Enzymes: An Experimental and Molecular Docking Study

Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation

Investigation of the inhibition effect of 1,2,3,4,6-pentagalloyl-β-D-glucose on gastric cancer cells based on a network pharmacology approach and experimental validation